Protalix Historical Income Statement

PLX Stock

USD 1.69 0.01 0.60%

Historical analysis of Protalix Biotherapeutics income statement accounts such as EBIT of 11 M, Ebitda of 12.2 M, Total Operating Expenses of 25 M or Income Before Tax of 9 M can show how well Protalix Biotherapeutics performed in making a profits. Evaluating Protalix Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protalix Biotherapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Protalix Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protalix Biotherapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

About Protalix Income Statement Analysis

Protalix Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protalix Biotherapeutics shareholders. The income statement also shows Protalix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Protalix Biotherapeutics Income Statement Chart

At this time, Protalix Biotherapeutics' Selling And Marketing Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 28.1 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024.

Selling General Administrative Other Operating Expenses Operating Income Total Operating Expenses Total Other Income Expense Net

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protalix Biotherapeutics. It is also known as Protalix Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Protalix Biotherapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Protalix Biotherapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Protalix Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling And Marketing Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 28.1 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	38.4M	47.6M	65.5M	68.8M
Depreciation And Amortization	1.1M	1.1M	1.2M	1.7M

Total Revenue Depreciation And Amortization

Protalix Biotherapeutics income statement Correlations

	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Depreciation And Amortization	Total Revenue	Gross Profit	Cost Of Revenue	Selling And Marketing Expenses	Research Development	Extraordinary Items	Net Income From Continuing Ops	Non Operating Income Net Other	Discontinued Operations	Net Interest Income	Interest Income	Reconciled Depreciation
Interest Expense		-0.17	0.52	-0.2	-0.19	-0.22	0.54	-0.53	-0.47	-0.4	0.05	-0.29	0.17	0.18	0.1	-0.07	0.48	0.19	-0.25	-0.42	-0.19	-0.1	-0.45	-0.12
Selling General Administrative	-0.17		0.11	0.45	0.44	0.45	-0.06	0.27	-0.05	0.2	0.0	-0.01	0.54	0.4	0.75	0.87	-0.09	-0.84	0.47	-0.14	-0.13	0.71	0.59	-0.47
Other Operating Expenses	0.52	0.11		-0.11	-0.09	-0.08	0.95	-0.24	-0.22	-0.43	0.31	0.07	0.52	0.51	0.39	0.26	0.8	0.14	0.08	-0.32	-0.37	0.3	0.01	-0.44
Operating Income	-0.2	0.45	-0.11		1.0	1.0	-0.22	0.69	-0.13	0.51	-0.06	-0.54	0.77	0.77	0.53	0.68	-0.13	-0.64	0.76	0.2	-0.17	0.61	0.46	-0.63
Ebit	-0.19	0.44	-0.09	1.0		1.0	-0.2	0.71	-0.11	0.49	-0.02	-0.54	0.78	0.78	0.54	0.68	-0.11	-0.63	0.77	0.21	-0.2	0.61	0.47	-0.65
Ebitda	-0.22	0.45	-0.08	1.0	1.0		-0.19	0.72	-0.09	0.5	-0.02	-0.5	0.78	0.78	0.53	0.68	-0.09	-0.63	0.79	0.23	-0.19	0.6	0.48	-0.64
Total Operating Expenses	0.54	-0.06	0.95	-0.22	-0.2	-0.19		-0.27	-0.15	-0.4	0.25	0.24	0.4	0.45	0.14	0.08	0.92	0.24	0.03	-0.24	-0.24	0.08	-0.2	-0.26
Income Before Tax	-0.53	0.27	-0.24	0.69	0.71	0.72	-0.27		0.61	0.6	0.12	-0.14	0.42	0.46	0.19	0.47	-0.15	-0.46	0.84	0.73	-0.07	0.4	0.58	-0.4
Total Other Income Expense Net	-0.47	-0.05	-0.22	-0.13	-0.11	-0.09	-0.15	0.61		0.22	0.3	0.35	-0.24	-0.21	-0.26	-0.05	-0.08	0.0	0.3	0.74	0.04	-0.09	0.29	0.14
Net Income	-0.4	0.2	-0.43	0.51	0.49	0.5	-0.4	0.6	0.22		-0.72	-0.14	0.11	0.19	-0.13	0.28	-0.36	-0.32	0.63	0.56	0.68	0.22	0.46	-0.16
Income Tax Expense	0.05	0.0	0.31	-0.06	-0.02	-0.02	0.25	0.12	0.3	-0.72		0.06	0.19	0.12	0.31	0.05	0.31	-0.01	-0.07	-0.05	-0.88	0.06	-0.06	-0.11
Depreciation And Amortization	-0.29	-0.01	0.07	-0.54	-0.54	-0.5	0.24	-0.14	0.35	-0.14	0.06		-0.38	-0.32	-0.45	-0.31	0.22	0.19	-0.12	0.16	0.17	-0.46	-0.2	0.57
Total Revenue	0.17	0.54	0.52	0.77	0.78	0.78	0.4	0.42	-0.24	0.11	0.19	-0.38		0.97	0.77	0.81	0.44	-0.59	0.68	-0.08	-0.41	0.75	0.34	-0.84
Gross Profit	0.18	0.4	0.51	0.77	0.78	0.78	0.45	0.46	-0.21	0.19	0.12	-0.32	0.97		0.61	0.7	0.51	-0.48	0.71	0.01	-0.33	0.62	0.27	-0.76
Cost Of Revenue	0.1	0.75	0.39	0.53	0.54	0.53	0.14	0.19	-0.26	-0.13	0.31	-0.45	0.77	0.61		0.87	0.12	-0.69	0.37	-0.32	-0.53	0.87	0.45	-0.82
Selling And Marketing Expenses	-0.07	0.87	0.26	0.68	0.68	0.68	0.08	0.47	-0.05	0.28	0.05	-0.31	0.81	0.7	0.87		0.08	-0.85	0.68	-0.03	-0.22	0.9	0.62	-0.81
Research Development	0.48	-0.09	0.8	-0.13	-0.11	-0.09	0.92	-0.15	-0.08	-0.36	0.31	0.22	0.44	0.51	0.12	0.08		0.11	0.07	-0.18	-0.27	0.07	-0.34	-0.25
Extraordinary Items	0.19	-0.84	0.14	-0.64	-0.63	-0.63	0.24	-0.46	0.0	-0.32	-0.01	0.19	-0.59	-0.48	-0.69	-0.85	0.11		-0.56	0.0	0.14	-0.67	-0.38	0.51
Net Income From Continuing Ops	-0.25	0.47	0.08	0.76	0.77	0.79	0.03	0.84	0.3	0.63	-0.07	-0.12	0.68	0.71	0.37	0.68	0.07	-0.56		0.62	-0.06	0.58	0.62	-0.6
Non Operating Income Net Other	-0.42	-0.14	-0.32	0.2	0.21	0.23	-0.24	0.73	0.74	0.56	-0.05	0.16	-0.08	0.01	-0.32	-0.03	-0.18	0.0	0.62		0.13	-0.06	0.36	0.02
Discontinued Operations	-0.19	-0.13	-0.37	-0.17	-0.2	-0.19	-0.24	-0.07	0.04	0.68	-0.88	0.17	-0.41	-0.33	-0.53	-0.22	-0.27	0.14	-0.06	0.13		-0.27	-0.04	0.31
Net Interest Income	-0.1	0.71	0.3	0.61	0.61	0.6	0.08	0.4	-0.09	0.22	0.06	-0.46	0.75	0.62	0.87	0.9	0.07	-0.67	0.58	-0.06	-0.27		0.71	-0.85
Interest Income	-0.45	0.59	0.01	0.46	0.47	0.48	-0.2	0.58	0.29	0.46	-0.06	-0.2	0.34	0.27	0.45	0.62	-0.34	-0.38	0.62	0.36	-0.04	0.71		-0.46
Reconciled Depreciation	-0.12	-0.47	-0.44	-0.63	-0.65	-0.64	-0.26	-0.4	0.14	-0.16	-0.11	0.57	-0.84	-0.76	-0.82	-0.81	-0.25	0.51	-0.6	0.02	0.31	-0.85	-0.46

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	8.0M	9.7M	7.5M	2.5M	3.2M	2.8M
Selling General Administrative	6.0M	5.1M	4.0M	13.6M	25.5M	26.7M
Other Operating Expenses	65.4M	60.2M	58.8M	60.7M	55.0M	31.5M
Operating Income	(10.7M)	1.8M	(20.5M)	(13.0M)	10.5M	11.0M
Ebit	(10.7M)	3.1M	(20.1M)	(11.9M)	10.5M	11.0M
Ebitda	(8.7M)	4.5M	(18.9M)	(10.8M)	11.7M	12.2M
Total Operating Expenses	54.5M	49.3M	42.5M	41.1M	32.1M	25.0M
Income Before Tax	(18.3M)	(6.5M)	(27.6M)	(14.4M)	8.6M	9.0M
Total Other Income Expense Net	(7.6M)	(9.2M)	(7.1M)	(1.4M)	(1.9M)	(1.8M)
Net Income	(26.2M)	(14.9M)	(34.0M)	(14.9M)	8.3M	8.7M
Income Tax Expense	8.0M	8.4M	6.4M	530K	254K	241.3K
Depreciation And Amortization	2.0M	1.3M	1.1M	1.1M	1.2M	1.7M
Total Revenue	54.7M	62.9M	38.4M	47.6M	65.5M	68.8M
Gross Profit	43.8M	52.0M	22.0M	28.0M	42.5M	44.6M
Cost Of Revenue	10.9M	10.9M	16.3M	19.6M	23.0M	24.1M
Selling And Marketing Expenses	15.9M	16.2M	16.7M	25.3M	40.4M	42.4M
Research Development	44.6M	38.2M	29.7M	29.3M	17.1M	28.1M
Net Income From Continuing Ops	(18.3M)	(6.5M)	(27.6M)	(14.9M)	8.3M	8.7M
Net Income Applicable To Common Shares	(18.3M)	(6.5M)	(27.6M)	(14.9M)	(13.4M)	(14.1M)
Net Interest Income	(7.6M)	(9.2M)	(7.1M)	(1.4M)	(1.9M)	(2.0M)
Interest Income	407K	438K	401K	1.1M	1.3M	686.3K
Reconciled Depreciation	1.6M	1.3M	1.1M	1.1M	1.2M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Historical Income Statement

About Protalix Income Statement Analysis

Protalix Biotherapeutics Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Protalix Biotherapeutics income statement Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics income statement Accounts

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Gross Profit	+ 0.97	Total Revenue
Total Operating Expenses	+ 0.95	Other Operating Expenses
Research Development	+ 0.92	Total Operating Expenses

Discontinued Operations	- 0.88	Income Tax Expense
Reconciled Depreciation	- 0.85	Net Interest Income
Extraordinary Items	- 0.85	Selling And Marketing Expenses
Reconciled Depreciation	- 0.84	Total Revenue
Extraordinary Items	- 0.84	Selling General Administrative
Reconciled Depreciation	- 0.82	Cost Of Revenue